Zhang S, Orita H, Fukunaga T. Current surgical treatment of esophagogastric junction adenocarcinoma. World J Gastrointest Oncol 2019; 11(8): 567-578 [PMID: 31435459 DOI: 10.4251/wjgo.v11.i8.567]
Corresponding Author of This Article
Tetsu Fukunaga, MD, PhD, Professor, Department of Gastroenterology and Minimally Invasive Surgery, Juntendo University Hospital, 3-1-3 Hongo, Bunkyo-ku, Tokyo 113-8431, Japan. t2fukunaga@juntendo.ac.jp
Research Domain of This Article
Surgery
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Aug 15, 2019; 11(8): 567-578 Published online Aug 15, 2019. doi: 10.4251/wjgo.v11.i8.567
Current surgical treatment of esophagogastric junction adenocarcinoma
Shun Zhang, Hajime Orita, Tetsu Fukunaga
Shun Zhang, Department of Gastroenterology Surgery, Shanghai East Hospital (East Hospital Affiliated to Tongji University), Shanghai 200120, China
Shun Zhang, Hajime Orita, Tetsu Fukunaga, Department of Gastroenterology and Minimally Invasive Surgery, Juntendo University Hospital, Tokyo 113-8431, Japan
Author contributions: All authors equally contributed to this paper with conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version.
Supported byJapan China Sasakawa Medical Fellowship.
Conflict-of-interest statement: No potential conflicts of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Tetsu Fukunaga, MD, PhD, Professor, Department of Gastroenterology and Minimally Invasive Surgery, Juntendo University Hospital, 3-1-3 Hongo, Bunkyo-ku, Tokyo 113-8431, Japan. t2fukunaga@juntendo.ac.jp
Telephone: +81-0358021556 Fax: +81-0358021557
Received: February 26, 2019 Peer-review started: February 27, 2019 First decision: June 4, 2019 Revised: June 26, 2019 Accepted: July 16, 2019 Article in press: July 16, 2019 Published online: August 15, 2019 Processing time: 171 Days and 2 Hours
Abstract
The incidence of esophagogastric junction (EGJ) adenocarcinoma has shown an upward trend over the past several decades worldwide. In this article, we review previous studies and aimed to provide an update on the factors related to the surgical treatment of EGJ adenocarcinoma. The Siewert classification has implications for lymph node spread and is the most commonly used classification. Different types of EGJ cancer have different incidences of mediastinal and abdominal lymph node metastases, and different surgical approaches have unique advantages and disadvantages. Minimally invasive surgeries have been increasingly applied in clinical practice and show comparable oncologic outcomes. Endoscopic resection may be a good therapy for early EGJ cancer. Additionally, there is still a great need for well-designed, large RCTs to forward our knowledge on the surgical treatment of EGJ cancer.
Core tip: This is a review article on the current strategies for the surgical management of esophagogastric junction (EGJ) cancer. This article covers the different aspects related with the surgical treatment of EGJ cancer and provides comparison between different modalities discussed.
